A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease
This study is investigating a new tablet called Venglustat for people aged 16 and older who have Fabry disease. The main goal is to see if Venglustat can ease nerve pain in the arms and legs, and tummy pain, compared to a placebo (a dummy tablet with no medicine). We are looking for people who haven't been treated for Fabry disease for at least six months, or who have never been treated before. Participants will take either Venglustat or the placebo for 12 months. After this, everyone will have the chance to take Venglustat in an open-label extension part of the study. Regular check-ups will happen about every three months to see how you are doing.
Auf einen Blick
Worum geht es in dieser Studie?
This study is focusing on Fabry disease, a rare genetic condition that can cause various health problems, including significant pain. Specifically, we are looking at nerve pain in the arms and legs (neuropathic pain) and tummy pain (abdominal pain).
We are testing a new medicine called Venglustat, which comes in tablet form. The main purpose of this research is to find out if Venglustat can help reduce these painful symptoms in people with Fabry disease. We compare it to a 'placebo', which looks exactly like the study medicine but doesn't contain any active drug. This helps us understand if the new medicine is truly effective.
This is a 'Phase 3' study, which means it's one of the final steps before a new medicine might become widely available. Doctors and scientists are hopeful that Venglustat could offer a new way to manage these challenging pain symptoms for people living with Fabry disease.
Wichtige Erkenntnisse
- Tests a new tablet (Venglustat) for Fabry disease pain.
- Compares Venglustat to a dummy tablet (placebo) first.
- Open to people aged 16+ who haven't recently been treated for Fabry.
- Involves regular check-ups (every 3 months) for up to 4 years.
- Sie können die Teilnahme jederzeit beenden.
- Ihre Gesundheit wird während des gesamten Prozesses genau überwacht.
Wer könnte berechtigt sein?
You might be able to join this study if you are 16 years old or older and have a confirmed diagnosis of Fabry disease with symptoms. We are looking for people who haven't received treatment for Fabry disease in the last six months, or who have never been treated for it before. A key part of joining is having an average pain score of 3 or more (on a scale of 0 to 10, where 10 is the worst pain imaginable) for either nerve pain in your arms or legs, or tummy pain.
However, there are reasons why you might not be able to take part. For example, if you have certain other serious health conditions like a recent heart attack, stroke, or uncontrolled high blood pressure. You also wouldn't be able to join if you have certain infections like Hepatitis C, HIV, or Hepatitis B, or if your pain is known to be caused by something other than Fabry disease.
If you're thinking about joining, it's important that you or your partner (if you are a man) are using effective birth control methods, and women should not be pregnant or breastfeeding. We also need to check your kidney function and other health markers to make sure it's safe for you to take part.
Könnte diese Studie für Sie geeignet sein?
Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.
- Sind Sie 16 Jahre alt oder älter?
- Do you have a diagnosis of Fabry disease with symptoms?
- Have you not received Fabry disease treatment for at least the past 6 months (or ever)?
- Do you experience nerve pain in your arms/legs or tummy pain, scoring 3 or more out of 10?
- Are you able to use effective birth control if required?
- Do you generally have good health apart from your Fabry disease?
Was beinhaltet die Teilnahme?
If you decide to join, the study will have two main parts. For the first 12 months, you will take either the study medicine (Venglustat) or a dummy tablet (placebo). Neither you nor your study doctor will know which one you are taking – this is called 'double-blind'. During this time, you'll have study visits about every three months to check on your health and how you're feeling.
After these 12 months, if you wish to continue and have completed the first part, you will enter an 'open-label' period. This means everyone will receive Venglustat, and both you and your doctor will know you're taking the active medicine. This part could last for another 12 months, or potentially longer, until all participants finish the study at the same time. The total time you could be in the study, including initial checks and follow-up, could be up to about 46 months (nearly 4 years). Throughout, there will be regular checks to make sure you are safe and that the medicine is well tolerated.
Potenzielle Risiken und Vorteile
Locations (50)
- University of Alabama -The Kirklin Clinic- Site Number : 8400011Verifizierte PostleitzahlBirmingham, Vereinigte Staaten
- David Geffen School of Medicine at UCLA- Site Number : 8400006Verifizierte PostleitzahlLos Angeles, Vereinigte Staaten
- University of California Irvine Medical Center- Site Number : 8400019Verifizierte PostleitzahlOrange, Vereinigte Staaten
- AdventHealth Orlando- Site Number : 8400008Verifizierte PostleitzahlOrlando, Vereinigte Staaten
- Emory University School of Medicine - Atlanta- Site Number : 8400010Verifizierte PostleitzahlAtlanta, Vereinigte Staaten
- WMCHealth Advanced Physician Services- Site Number : 8400001Verifizierte PostleitzahlHawthorne, United States
- Cincinnati Children's Hospital Medical Center- Site Number : 8400013Verifizierte PostleitzahlCincinnati, Vereinigte Staaten
- UPMC Montefiore- Site Number : 8400009Verifizierte PostleitzahlPittsburgh, United States
- Renal Disease Research Institute - Dallas - Live Oak Street- Site Number : 8400012Verifizierte PostleitzahlDallas, Vereinigte Staaten
- University of Utah Health Hospital- Site Number : 8400005Verifizierte PostleitzahlSalt Lake City, Vereinigte Staaten
- Lysosomal and Rare Disorders Research and Treatment Center (LDRTC)- Site Number : 8400004Verifizierte PostleitzahlFairfax, Vereinigte Staaten
- Investigational Site Number : 0320001Verifizierte PostleitzahlPergamino, Argentina
Häufige Fragen
What is Fabry disease?
Fabry disease is a rare genetic condition that can affect many parts of the body, including the nerves, kidneys, and heart, often causing pain and other symptoms.
Was bedeutet 'Placebo'?
A placebo is a dummy tablet that looks exactly like the study medicine but doesn't contain any active drug. It helps researchers compare the new medicine's effects.
Wie lange werde ich an der Studie teilnehmen?
The first main part of the study is 12 months. If you continue, the study could last up to about 46 months (nearly 4 years) in total.
Will I know if I'm getting the active medicine?
For the first 12 months, neither you nor your doctor will know if you're taking Venglustat or the placebo. After that, if you continue, you will know you are taking Venglustat.
What kind of pain is the study looking at?
This study is focused on nerve pain in the arms and legs, and tummy pain, that is related to your Fabry disease.
Wie Sie mehr erfahren können
Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.
Diskussion
Community-Diskussion
Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.